Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: From the Danish "MALOVA" ovarian carcinoma study

Cancer

Volumn 100, Issue 11, 2004, Pages 2387-2395

  Høgdall, Estrid V S ^a,b   Ryan, Andy ^c   Kjaer, Susanne K ^a   Blaakaer, Jan ^d   Christensen, Lise ^e   Bock, Johannes E ^e   Glud, Eva ^a   Jacobs, Ian J ^c   Høgdall, Claus K ^e  

^a INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Loss of heterozygosity (LOH); Microsatellite markers; Ovarian carcinoma (OC); Prognostic factors

Indexed keywords

TETRANECTIN;

ADULT; AGED; ALLELE; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; DENMARK; FEMALE; GEL ELECTROPHORESIS; GENE FUNCTION; HETEROZYGOSITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROSATELLITE MARKER; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE; X CHROMOSOME;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; CALCIUM CHANNELS; CARCINOMA, ENDOMETRIOID; CHROMOSOMES, HUMAN, X; CYSTADENOCARCINOMA, SEROUS; DENMARK; DNA, NEOPLASM; FEMALE; GENES, P53; HUMANS; LECTINS, C-TYPE; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PROGNOSIS; SURVIVAL RATE;

EID: 2442704418     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20213     Document Type: Article

References (39)

1. Kjaer SK, Ewertz M. Ovarian cancer in Denmark 1943-1982. Ugeskr Læger. 1987;149:3356-3360.
2. Kjaer SK, Storm HH. Female genital organs. In: Carstensen B, Storm HH, Schou G, editors. Survival of Danish cancer patients 1943-1987. Supplement 33. Copenhagen: APMIS, Munksgaard, 1993;107-121.
3. Qazi F, McGuire WP. The treatment of epithelial ovarian cancer. CA Cancer J Clin. 1995;45:88-101.
4. Young RC, Walton LA, Ellenberg SS et al. Adjuvant therapy in Stage I and Stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med. 1990;322:1021-1027.
5. Bjorge T, Engeland A, Sundfor K, Trope CG. Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital. Acta Obstet Gynecol Scand. 1998;77:777-781.
6. Knudson AG. All in the (cancer) family. Nat Genet. 1993;5:103-104.
7. Otis CN, Krebs PA, Quezado MM et al. Loss of heterozygosity in P53, BRCA1, and estrogen receptor genes and correlation to expression of p53 protein in ovarian epithelial tumors of different cell types and biological behavior. Hum Pathol. 2000;31:233-238.
8. Gabra H, Watson JE, Taylor KJ et al. Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer Res. 1996;56:950-954.
9. Shelling AN, Cooke IE, Ganesan TS. The genetic analysis of ovarian cancer. Br J Cancer. 1995;72:521-527.
10. Jiang X, Hitchcock A, Bryan EJ et al. Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci. Cancer Res. 1996;56:3534-3539.
11. Zheng JP, Robinson WR, Ehlen T, Yu MC, Dubeau L. Distinction of low grade from high grade human ovarian carcinomas on the basis of losses of heterozygosity on chromosomes 3, 6, and 11 and HER-2/neu gene amplification. Cancer Res. 1991;51:4045-4051.
12. Launonen V, Mannermaa A, Stenback F et al. Loss of heterozygosity at chromosomes 3, 6, 8, 11, 16, and 17 in ovarian cancer: correlation to clinicopathological variables. Cancer Genet Cytogenet. 2000;122:49-54.
13. Pieretti M, Hopenhayn-Rich C, Khattar NH, Cao Y, Huang B, Tucker TC. Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Cancer Invest. 2002;20:11-23.
14. Yang Feng TL, Li S, Han H, Schwartz PE. Frequent loss of heterozygosity on chromosomes Xp and 13q in human ovarian cancer. Int J Cancer. 1992;52:575-580.
15. Buekers TE, Lallas TA, Buller RE. Xp22.2-3 loss of heterozygosity is associated with germline BRCA1 mutation in ovarian cancer. Gynecol Oncol. 2000;76:418-422.
16. Pieretti M, Powell DE, Gallion HH, Case EA, Conway PS, Turker MS. Genetic alterations on chromosome 17 distinguish different types of epithelial ovarian tumors. Hum Pathol. 1995;26:393-397.
17. Åstedt B, Svanberg L, Nilsson IM. Fibrin degration products and ovarian tumors. BMJ. 1971;4:458-459.
18. Peterson HI, Kjartansson I, Korsan-Bengtsen K, Rudenstam CM, Zettergren L. Fibrinolysis in human malignant tumors. Acta Chir Scand. 1973;139:219-223.
19. Malone JM, Wangensteen SL, Moore WS, Keown K. The fibrinolytic system: a key to tumor metastasis. Ann Surg. 1979;190:342-348.
20. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139-266.
21. Zacharski LR, Wojtukiewicz MZ, Costantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost. 1992;18:104-116.
22. Høgdall CK, Christensen L, Clemmensen I. The prognostic value of tetranectin immunoreactivity and plasma tetranectin in patients with ovarian cancer. Cancer. 1993;72:2415-2422.
23. Høogdall CK, Høgdall EVS, Hørding U, Clemmensen I, Nørgaard-Pedersen B, Toftager-Larsen K. Preoperative plasma tetranectin as a prognostic marker in ovarian cancer patients. Scand J Clin Lab Invest. 1993;53:741-746.
24. Lee JH, Kavanagh JJ, Wildrick DM, Wharton JT, Blick M. Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas. Cancer Res. 1990;50:2724-2728.
25. Lassus H, Salovaara R, Aaltonen LA, Butzow R. Allelic analysis of serous ovarian carcinoma reveals two putative tumor suppressor loci at 18q22-q23 distal to SMAD4, SMAD2, and DCC. Am J Pathol. 2001;159:35-42.
26. Høgdall EVS, Høgdall CK, Christensen L, et al. Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients. Anticancer Res. 2002;22:1859-1864.
27. Høgdall EV, Christensen L, Kjaer SK, et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer. 2003; 98:66-73.
28. Høgdall EV, Høgdall CK, Blaakaer J, et al. P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis. APMIS. 2002;110: 545-553.
29. Høogdall EV, Høgdall CK, Blaakaer J, et al. K-ras alterations in Danish ovarian tumour patients. From the Danish "MALOVA" ovarian cancer study. Gynecol Oncol. 2003;89: 31-36.
30. Walsh PS, Metzger DA, Higuchi R. Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. Biotechniques. 1991;10:506-513.
31. Shahin MS, Hughes JH, Sood AK, Buller RE. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer. 2000;89:2006-2017.
32. Høgdall CK, Høgdall EVS, Hørding U, et al. Plasma tetranectin and ovarian neoplasms. Gynecol Oncol. 1991;43:103-107.
33. Høgdall CK. Human tetranectin: methodological and clinical studies. APMIS Suppl. 1998;86:1-31.
34. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187-220.
35. Buller RE, Sood AK, Lallas T, Buekers T, Skilling JS. Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer. J Natl Cancer Inst. 1999;91:339-346.
36. Buller RE, Sood AK, Lallas T, Buekers T, Skilling JS. RESPONSE. Re: association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer. J Natl Cancer Inst. 1999;91:1508-1509.
37. Manderson EN, Presneau N, Provencher D, Mes-Masson AM, Tonin PN. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer. Mol Carcinog. 2002;34:78-90.
38. Pieretti M, Turker MS. Mutation, ageing, and ovarian cancer. Lancet. 1997;349:700-701.
39. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J, Munkarah AR. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol. 2003;189:1120-1127.